The stock of Akari Therapeutics Plc Adr (NASDAQ:AKTX) registered an increase of 1.3% in short interest. AKTX’s total short interest was 23,400 shares in September as published by FINRA. Its up 1.3% from 23,100 shares, reported previously. With 4,000 shares average volume, it will take short sellers 6 days to cover their AKTX’s short positions. The short interest to Akari Therapeutics Plc Adr’s float is 0.69%. About 503 shares traded hands. Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) has declined 28.24% since February 8, 2016 and is downtrending. It has underperformed by 44.73% the S&P500.
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. The company has a market cap of $111.84 million. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 , including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. It currently has negative earnings. The Company’s lead drug, Coversin, a complement inhibitor, acts on complement C5, preventing release of C5a and formation of C5b-9.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.